"Unifuzol®" in Patients With Peripheral Arterial Disease
Status:
Completed
Trial end date:
2019-10-26
Target enrollment:
Participant gender:
Summary
The present study is a multicenter, randomized, double-blind, placebo-controlled study of the
safety and efficacy of the drug Unifuzol® (L-arginine) in patients with obliterating
atherosclerosis of the lower extremities. The study recruits patients 40-79 years old with a
confirmed diagnosis of chronic ischemia of the lower limb and a stable symptom of
intermittent claudication that occurs when walking a distance of 100-299 meters. L-arginine
improves microcirculation due to activation of nitrogen monoxide production and stimulates
capillary blood flow, thus can probably improve the quality of life of patients with
intermittent claudication. The criterion for treatment efficacy will be an increase in the
maximum walking distance measures before and on the next day after the end of treatment
course.
Phase:
Phase 2
Details
Lead Sponsor:
POLYSAN Scientific & Technological Pharmaceutical Company